These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

722 related items for PubMed ID: 34081614

  • 1. MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people.
    Glintborg D, T'Sjoen G, Ravn P, Andersen MS.
    Eur J Endocrinol; 2021 Jun 28; 185(2):R49-R63. PubMed ID: 34081614
    [Abstract] [Full Text] [Related]

  • 2. Endocrinology of Transgender Medicine.
    T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V.
    Endocr Rev; 2019 Feb 01; 40(1):97-117. PubMed ID: 30307546
    [Abstract] [Full Text] [Related]

  • 3. Gender-affirming hormone treatment: friend or foe? Long-term follow-up of 755 transgender people.
    Santi D, Spaggiari G, Marinelli L, Cacciani M, Scipio S, Bichiri A, Profeta A, Granata ARM, Simoni M, Lanfranco F, Manieri C, Ghigo E, Motta G.
    J Endocrinol Invest; 2024 May 01; 47(5):1091-1100. PubMed ID: 37889433
    [Abstract] [Full Text] [Related]

  • 4. Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study.
    Muir CA, Guttman-Jones M, Man EJ.
    Endocrine; 2024 Jul 01; 85(1):370-379. PubMed ID: 38386168
    [Abstract] [Full Text] [Related]

  • 5. Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy.
    Shepherd R, Angus LM, Mansell T, Arman B, Kim BW, Lange K, Burgner D, Kerr JA, Pang K, Zajac JD, Saffery R, Cheung A, Novakovic B.
    J Clin Endocrinol Metab; 2024 Oct 15; 109(11):2857-2871. PubMed ID: 38609170
    [Abstract] [Full Text] [Related]

  • 6. Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations.
    Jasuja GK, Wolfe HL, Reisman JI, Vimalananda VG, Rao SR, Blosnich JR, Livingston NA, Shipherd JC.
    Front Endocrinol (Lausanne); 2024 Oct 15; 15():1086158. PubMed ID: 38800485
    [Abstract] [Full Text] [Related]

  • 7. Hormone Therapy for Transgender Adults.
    Radix A.
    Urol Clin North Am; 2019 Nov 15; 46(4):467-473. PubMed ID: 31582021
    [Abstract] [Full Text] [Related]

  • 8. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
    Burinkul S, Panyakhamlerd K, Suwan A, Tuntiviriyapun P, Wainipitapong S.
    J Sex Med; 2021 Jul 15; 18(7):1299-1307. PubMed ID: 34274044
    [Abstract] [Full Text] [Related]

  • 9. Thrombotic risk associated with gender-affirming hormone therapy.
    Mullins TLK, Mullins ES.
    J Thromb Haemost; 2024 Aug 15; 22(8):2129-2139. PubMed ID: 38795871
    [Abstract] [Full Text] [Related]

  • 10. Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks.
    Sudhakar D, Huang Z, Zietkowski M, Powell N, Fisher AR.
    Neurourol Urodyn; 2023 Jun 15; 42(5):903-920. PubMed ID: 36403287
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Short-Term Effects of Gender-Affirming Hormone Therapy on Dysphoria and Quality of Life in Transgender Individuals: A Prospective Controlled Study.
    Foster Skewis L, Bretherton I, Leemaqz SY, Zajac JD, Cheung AS.
    Front Endocrinol (Lausanne); 2021 Jun 15; 12():717766. PubMed ID: 34394009
    [Abstract] [Full Text] [Related]

  • 13. Testosterone and other treatments for transgender males and non-binary trans masculine individuals.
    Dimakopoulou A, Seal LJ.
    Best Pract Res Clin Endocrinol Metab; 2024 Sep 15; 38(5):101908. PubMed ID: 38997938
    [Abstract] [Full Text] [Related]

  • 14. Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: a randomized controlled trial.
    Dijkman BAM, Helder D, Boogers LS, Gieles NC, van Heesewijk JO, Slaa ST, Liberton NPTJ, Wiepjes CM, de Blok CJM, den Heijer M, Dreijerink KMA.
    BMC Pharmacol Toxicol; 2023 Dec 20; 24(1):80. PubMed ID: 38124194
    [Abstract] [Full Text] [Related]

  • 15. Gender-Affirming Hormone Use in Transgender Individuals: Impact on Behavioral Health and Cognition.
    Nguyen HB, Chavez AM, Lipner E, Hantsoo L, Kornfield SL, Davies RD, Epperson CN.
    Curr Psychiatry Rep; 2018 Oct 11; 20(12):110. PubMed ID: 30306351
    [Abstract] [Full Text] [Related]

  • 16. Hormone Concentrations in Transgender Women Who Self-Prescribe Gender Affirming Hormone Therapy: A Retrospective Study.
    Salakphet T, Mattawanon N, Manojai N, Muangmool T, Tangpricha V.
    J Sex Med; 2022 May 11; 19(5):864-871. PubMed ID: 35379590
    [Abstract] [Full Text] [Related]

  • 17. Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective.
    Sagar RC, Millson-Brown V.
    Best Pract Res Clin Endocrinol Metab; 2024 Sep 11; 38(5):101921. PubMed ID: 39232976
    [Abstract] [Full Text] [Related]

  • 18. Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans.
    Hashemi L, Marijic Buljubasic A, Budoff MJ, Copeland LA, Jackson NJ, Jasuja GK, Gornbein J, Reue K.
    JAMA Netw Open; 2024 Jul 01; 7(7):e2419696. PubMed ID: 38954413
    [Abstract] [Full Text] [Related]

  • 19. Transfeminine Hormone Therapy.
    Hamidi O, Davidge-Pitts CJ.
    Endocrinol Metab Clin North Am; 2019 Jun 01; 48(2):341-355. PubMed ID: 31027544
    [Abstract] [Full Text] [Related]

  • 20. Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women.
    Haupt C, Henke M, Kutschmar A, Hauser B, Baldinger S, Saenz SR, Schreiber G.
    Cochrane Database Syst Rev; 2020 Nov 28; 11(11):CD013138. PubMed ID: 33251587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.